Cadila Pharma launches fenticonazole pills for vulvovaginal candidiasis

July 19, 2020 0 By FM

Cadila Pharmaceuticals Ltd has recently announced the launch of fenticonazole nitrate (Fenticad) capsules for the treatment of vulvovaginal candidiasis (VVC). The drug will be made available in 600 mg tablets.

Vulvovaginal candidiasis refers to vaginal and vulval symptoms caused by a yeast, most often Candida albicans. VVC affects up to 75% of women once in their lifetime and severely impacts their quality of life. Itching (pruritus) and increased vaginal discharge are the most typical symptoms. Other symptoms are variable: soreness and burning, dyspareunia, or dysuria.

Diabetes, pregnancy, inadequate intimate hygiene, unprotected and intense sexual activity, and antibiotic treatment can lead to a high risk of developing VVC. During pregnancy, topical antifungal treatment (such as fenticonazole, clotrimazole, fluconazole) formulated as vaginal capsules or cream is preferred.